Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,237 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Single Agent Therapy Clear all
Completed No phase listed Observational

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting

NCT03160040
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Minocycline IV
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting Phase 3 Interventional

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
30
States / cities
Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABBV-453, Daratumumab, Dexamethasone, Pomalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

NCT07087860
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
17
States / cities
Duarte, California • La Jolla, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 1 Interventional

Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI

NCT03084523
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis
Interventions
Ferumoxytol Injectable Product
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 2, 2026, 5:37 AM EDT
Terminated Phase 1 Interventional

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

NCT04672980
View directory record Official record
Conditions
Cervical Cancer, Head and Neck Cancer, Anal Cancer
Interventions
RTX-321
Drug
Lead sponsor
Rubius Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 2, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional Results available

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

NCT04812535
View directory record Official record
Conditions
SCC - Squamous Cell Carcinoma of Skin
Interventions
Vilobelimab, Vilobelimab + pembrolizumab combination therapy
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
La Jolla, California • Aurora, Colorado • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 2, 2026, 5:37 AM EDT
Temporarily Not Available No phase listed Expanded access

RAPA-501 Therapy of ALS Expanded Access Protocol

NCT06169176
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
RAPA-501 Autologous T stem cells
Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Enrolling by invitation Phase 4 Interventional

Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover

NCT07230340
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Amnion-Intermediate-Chorion, Standard of Care (SOC)
Other · Procedure
Lead sponsor
Cellution Biologics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568
View directory record Official record
Conditions
Endometrial Cancer
Interventions
BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
14
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting No phase listed Observational

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

NCT07763197
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 4 Interventional Results available

Mechanism of Action Study for Psoriasis

NCT00932113
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Adalimumab (Humira)
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

NCT07195682
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
BMS-986506, Pumitamig, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

NCT00017082
View directory record Official record
Conditions
Colorectal Cancer
Interventions
oxaliplatin
Drug
Lead sponsor
Prologue Research International
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Boca Raton, Florida • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 2, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional Results available

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

NCT00365274
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate, prednisone, SGN-30
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 2, 2026, 5:37 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

NCT04445220
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Sepsis
Interventions
SBI-101
Biological
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 2, 2026, 5:37 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00073385
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pivanex, Docetaxel
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
5
States / cities
La Verne, California • New Orleans, Louisiana • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2005 · Synced Sep 2, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

NCT03246685
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Imprime PGG, Pembrolizumab
Biological · Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 1 Interventional

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176
View directory record Official record
Conditions
Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
AZD5153, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 2, 2026, 5:37 AM EDT
Terminated Phase 1 Interventional

Study of GS-1219 in Participants With HIV-1

NCT07115368
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-1219, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 2, 2026, 5:37 AM EDT
Active, not recruiting Not applicable Interventional

Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate

NCT05155891
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Embosphere Microspheres, HoLEP Procedure
Device · Procedure
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Enrolling by invitation Phase 2 Interventional

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

NCT05669989
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 5:37 AM EDT